Why Brain Trust Accelerator Funds Succeed

The convergence of science, technology and market forces is creating a rare opportunity in the field of brain-related diseases. Many venture funds were designed to invest in later-stage treatments with a higher chance of success. Opportunities for funding early-stage, translational research in brain-related diseases is the hallmark of Brain Trust Accelerator Funds.

With the scientific advancement by the genomic sequencing of normal and disease states, we are able to identify molecular and genomic abnormalities. This now provides the opportunity to address brain diseases early in the manifestation, potentially before symptoms occur. Today we have the tools to more precisely convert research observations into clinical practice - from both diagnostic and therapeutic perspectives - enabling optimal therapy for individual patients. And due to the aging of the baby boomer population, the market is large and growing, with an emphasis on quality of life and mental acuity.

The Brain Trust Accelerator Funds capitalize on our experience in brain-related diseases, our operational as well as venture capital experience, the potential deal flow from philanthropies, and our focus on social as well as economic considerations.

There is also an emergence of a new class of philanthropy that is focused on enabling the rapid transformation of pioneering research into meaningful clinical benefit for patients. These philanthropies can initiate the process of such transformation but require additional financing and additional skills to develop promising new opportunities into viable and attractive commercial successes. The Brain Trust Accelerator Funds have provided a portion of additional financial capital as well as expertise and skills to philanthropies.